RxDoctor Payments Data

Alexandra Zhakov

Physician Assistant · Wethersfield, CTNPI 1184220865

Payments from drug & device makers

$4,224in general payments, 2019–2025

Across 132 payments — averaging $32.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Novo Nordisk$576
  • Abbott$369
  • Novartis$323
  • Johnson & Johnson$271
  • AstraZeneca$249
  • plus $1K from 14 others

What the payments were for

  • Travel & lodging$60114%
  • Food & beverage$3,62486%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,224 in reported general payments places this provider in the 90th percentile of 1,795 physician assistant providers in Connecticut.

See all physician assistant providers in Connecticut

Medicare billing

Part B allowed, 2024
$52,117
Medicare patients
301
Services billed
888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban150$215,165
FarxigaDapagliflozin Propanediol49$59,501
JardianceEmpagliflozin33$47,432
XareltoRivaroxaban29$30,700
EntrestoSacubitril/Valsartan19$30,066
Repatha SureclickEvolocumab22$20,338
OzempicSemaglutide18$17,060
Metoprolol Succinate246$3,042
Torsemide90$2,174
Atorvastatin Calcium123$1,397
Diltiazem 24hr Er (Cd)Diltiazem Hcl56$1,160
Rosuvastatin Calcium89$1,023
Amlodipine Besylate119$811
Nebivolol Hcl13$676
Spironolactone69$671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$230$215,165150 claims
AstraZenecaFarxiga$249$59,50149 claims
Boehringer IngelheimJardiance$242$47,43233 claims
Johnson & JohnsonXarelto$271$30,70029 claims
NovartisEntresto$323$30,06619 claims
Novo NordiskOzempic$576$17,06018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,795 physician assistant providers in Connecticut.

Other physician assistant in Wethersfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →